New Tests Available for Cervical and Other Genital HPV Cancers

A molecular laboratory service now offers new human papillomavirus (HPV) testing of low- and high-risk genotypes using cutting-edge technology, including next- generation DNA sequencing (NGS) platforms.

Genital human papillomaviruses (HPV) are a group of more than 40 related viruses. 14 high-risk genotypes are associated with most cases of cervical cancer and anal cancers; many vaginal, vulvar, and penile cancers; and some oropharyngeal cancers. Two genotypes, HPV 16 and HPV 18, are responsible for about 70% of all cervical cancers. HPV testing is recommended as part of routine cervical cancer screening for women 30 to 65 years of age, along with Pap smears every 5 years.

Medical Diagnostic Laboratories, LLC (MDL; Hamilton, NJ, USA), and its division the Institute for Biomarker Research, have announced now offering a diverse panel for high-accuracy genetic HPV testing. The MDL “HPV Type-Detect 3.0” tests identify the presence of DNA from: 5 low-risk HPV genotypes: HPV 6, 11, 42, 43, 44; and 14 high-risk genotypes: HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68. MDL's HPV reflex testing includes HPV 16 and HPV 18 RNA expression, HPV 16 viral load, HPV 16 integration status and E6 variants at no additional charge.

Minimally-invasive, simple specimen collection methods are provided: cervico-vaginal swabs for females utilizing the OneSwab or ThinPrep platforms, or urine for males utilizing the UroSwab platform.

MDL’s Institute for Biomarker Research division was established to create, validate, and commercialize innovative diagnostic assays for clinical practice. MDL, a member of the Genesis Biotechnology Group (Hamilton, NJ, USA), is a CLIA-certified, CAP-accredited laboratory specializing in high complexity, state-of-the-art, automated DNA-based molecular analyses.

Related Links:
Medical Diagnostic Laboratories